HR and breast carcinoma: Previously, mutations affecting the PIK3CA gene, which results in the hyperactivation of the alpha isoform (p110a) of PI3K, have been demonstrated in 28% to 46% of patients with HR+/(HER2−) advanced breast cancers [21].